SCHEMBL1504345

SCHEMBL1504345

N#CC=CC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504344 1.00
SCHEMBL2251117 1.00
SCHEMBL15940330 0.88
SCHEMBL99597 0.88
SCHEMBL99596 0.88
SCHEMBL2253136 0.88
SCHEMBL2253133 0.88
SCHEMBL101534 0.88
SCHEMBL521914 0.86 ALDH1A1 (0.35)
SCHEMBL521913 0.86 ALDH1A1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 EP claimed
CN-117810530-A In-situ polymerization high-voltage-resistant semi-solid electrolyte, preparation method thereof and lithium metal semi-solid battery 四川启睿克科技有限公司 2024-04-02 CN claimed
CN-117410439-A Electrode plate, preparation method thereof and battery 蜂巢能源科技股份有限公司 2024-01-16 CN claimed
EP-4138836-A1 TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND OTHER DISORDERS INVOLVING CYTOKINE STORM USING BTK INHIBITORS Principia Biopharma Inc. (US) 2023-03-01 EP claimed
CN-115443136-A Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using BTK inhibitors 普林斯匹亚生物制药公司 2022-12-06 CN claimed
EP-3478687-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2019-05-08 EP claimed
WO-2018004306-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-01-04 WO claimed
EP-2861599-A1 REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES Principia Biopharma Inc. (US) 2015-04-22 EP claimed
EP-2710005-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2014-03-26 EP claimed
WO-2013191965-A1 REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES PRINCIPIA BIOPHARMA INC. (US) 2013-12-27 WO claimed
WO-2012158764-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2012-11-22 WO claimed
US-20110207835-A1 Alpha, Beta, Unsaturated Nitriles as Fragrances GIVAUDAN SA (CH) 2011-08-25 US claimed
EP-2079436-B1 ALPHA, BETA, UNSATURATED NITRILES AS FRAGRANCES GIVAUDAN SA (CH) 2010-11-10 EP claimed
CN-101516324-A Alpha, beta-unsaturated nitriles as fragrances GIVAUDAN SA (CH) 2009-08-26 CN claimed
EP-2079436-A1 ALPHA, BETA, UNSATURATED NITRILES AS FRAGRANCES Givaudan SA (CH) 2009-07-22 EP claimed
WO-2008037105-A1 ALPHA, BETA, UNSATURATED NITRILES AS FRAGRANCES GIVAUDAN SA (CH) 2008-04-03 WO claimed
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE HOLDINGS CORP (US) 2025-11-06 US disclosed
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 US disclosed
EP-0038575-B1 CYANOVINYL-CYCLOPROPANECARBOXYLIC ACIDS AND METHOD OF PREPARING THESE COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1983-03-09 EP disclosed
EP-0038575-A2 Cyanovinyl-cyclopropanecarboxylic acids and method of preparing these compounds AMERICAN CYANAMID COMPANY (US) 1981-10-28 EP disclosed